Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Globus Medical (GMED)

Globus Medical stockholders approve 1 million share increase to equity incentive plan

Neutral Impact 2 of 5 shareholder Written later

At its June 3, 2026 annual meeting, Globus Medical stockholders approved an amendment raising the shares authorized under its 2021 Equity Incentive Plan by 1,000,000, to 12,000,000 Class A shares. Stockholders also re-elected director Keith W. Pfeil and elected Robert A. Douglas to Class II terms, ratified Deloitte & Touche LLP as auditor for 2026, and approved executive compensation on an advisory basis.

Key points

  • Equity plan amendment: 246,228,534 for, 75,266,538 against, 79,135 abstain, 6,902,949 broker non-votes
  • Total shares authorized under the plan rise to 12,000,000 from 11,000,000 for incentive stock options, which are now 12,000,000
  • Director votes: Keith W. Pfeil 293,453,432 for and 28,120,775 withheld; Robert A. Douglas 311,683,904 for and 9,890,303 withheld
  • Deloitte & Touche LLP ratified for fiscal year ending December 31, 2026, with 327,965,803 for and 467,955 against

The filing

CompanyGlobus Medical (GMED)
Form8-K, current report
Filed with the SECJun 4, 2026, 4:11 PM ET
Accession number0001628280-26-040784

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.